Core Viewpoint - Shares of Tilray Brands (NASDAQ: TLRY) surged approximately 40% this week, primarily driven by a pro-CBD video posted by former President Donald Trump on his Truth Social account [1][10]. Group 1: Market Reaction - The significant increase in Tilray's stock price was largely attributed to Trump's endorsement of CBD, which is known for its medical benefits without the psychoactive effects associated with other cannabis compounds [1][4]. - The post positively impacted the entire cannabis sector, as many companies, including Tilray, offer CBD products alongside their cannabis offerings [7][10]. Group 2: Company Developments - Tilray announced an expansion of its medical marijuana cannabis flower offerings in Germany, a market that has legalized both medical and recreational cannabis [2][8]. - The company has diversified its product portfolio to include recreational cannabis in Canada, medical cannabis in Europe, CBD beverages in various markets including the U.S., and recently, alcoholic beverages [7]. Group 3: Regulatory Context - Despite the legalization of CBD under the 2018 Farm Bill, cannabis remains illegal at the federal level in the U.S., and the FDA does not permit CBD in food supplements [5]. - The Trump administration's apparent support for CBD as a cost-effective alternative to expensive pharmaceuticals could signal a shift in regulatory attitudes towards cannabis products [6].